Prestigious award recognizes Dr. Crooke’s outstanding research contributions in advancing biomedical science

n-Lorem, a nonprofit foundation, today announced that n-Lorem founder and CEO, Stanley Crooke, M.D., Ph.D., has been awarded the 2022 Steven C. Beering Award. This award recognizes Dr. Crooke’s seminal work in pioneering a new drug discovery platform that harnesses the power of antisense oligonucleotides (ASOs) to target genetic disorders and the field-changing implications that Dr. Crooke’s outstanding work has had, and will continue to have, in biomedical sciences.

The Steven C. Beering Award is given by Indiana University School of Medicine to one person each year. It honors an internationally recognized individual for outstanding research contributions to advancing biomedical or clinical science. In selecting Dr. Crooke for the award, the committee recognizes Dr. Crooke’s lifetime dedication in creating and advancing ASO technology to alter the expression of genes and ultimately disease-causing proteins. It is through the efforts led by Dr. Crooke that ASO technology is now a highly regarded, validated, versatile and efficient drug discovery platform that has, and will continue to change, the landscape of untreatable diseases. Past winners of this prestigious award include Dr. George Church, Dr. William Kaelin, and Dr. George Stark.

Dr. Crooke founded n-Lorem Foundation in 2020 as the first, industrialized non-profit foundation to meet the challenges of some of the rarest of rare patients – nano-rare patients, which have illnesses so rare that fewer than 30 people worldwide are afflicted with them. These patients often have no treatment options because their illnesses are too rare for for-profit companies to invest in the research and development of therapies. Once n-Lorem discovers and develops a personalized treatment for each individual nano-rare patient, the ASO therapy is provided free for life.

As a hands-on scientific leader his entire career, Dr. Crooke is credited with inventing, advancing and validating a new drug discovery platform, RNA-targeted drug discovery, and using this platform to discover and develop life-changing therapies. Over the course of his career, Dr. Crooke has led the discovery and development of hundreds of drugs, including more than 23 commercialized drugs, and published more than 500 scientific publications.

The Steven C. Beering Award for the advancement of biomedical science will be presented to Dr. Crooke today at the Indiana University School of Medicine during a lecture and award presentation.

About IU School of Medicine

IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability.

About n-Lorem

n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem has received over 200 applications for treatment with approximately 100 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.

To learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these patients and families in need.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230908220979/en/